Deferiprone as Parkinson's disease modifier: quantification of 3-O-methyldopa/l-dopa plasmatic ratio in patients

被引：0
|
作者：
Charbonnier-Beaupel, F. [1 ]
Bihan, K. [1 ]
Zahr, N. [1 ]
Corvol, J. C. [1 ]
Devos, D. [2 ]
机构：
[1] Pitie Salpetriere, Paris, France
[2] CHU Lille, F-59037 Lille, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2013年 / 27卷
关键词：
Parkinson's disease; deferiprone; disease modifier; metabolic ratio;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：73 / 74
页数：2
相关论文
共 50 条
  • [21] Simultaneous determination of levodopa and 3-O-methyldopa in patients with parkinson's disease by high-performance liquid chromatography with electrochemical detection
    Adamiak-Giera, Urszula
    Gawronska-Szklarz, Barbara
    JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES, 2018, 41 (19-20) : 1047 - 1051
  • [22] The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease
    Heikkinen, H
    Nutt, JG
    LeWitt, PA
    Koller, WC
    Gordin, A
    CLINICAL NEUROPHARMACOLOGY, 2001, 24 (03) : 150 - 157
  • [23] L-dopa therapy for Parkinson's disease: Past, present, and future
    Nagatsu, Toshiharu
    Sawada, Makoto
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S3 - S8
  • [24] Saccadic latency distributions in Parkinson’s disease and the effects of l-dopa
    A. W. Michell
    Z. Xu
    D. Fritz
    S. J. G. Lewis
    T. Foltynie
    C. H. Williams-Gray
    T. W. Robbins
    R. H. S. Carpenter
    R. A. Barker
    Experimental Brain Research, 2006, 174 : 7 - 18
  • [25] Duration of L-dopa and dopamine agonist monotherapy in Parkinson's disease
    Nissen, T.
    Newman, E. J.
    Grosset, K. A.
    Daghem, M.
    Pal, G.
    Stewart, M.
    Odin, P.
    Macphee, G. J.
    Grosset, D. G.
    SCOTTISH MEDICAL JOURNAL, 2012, 57 (04) : 217 - 220
  • [26] Saccadic latency distributions in Parkinson's disease and the effects of L-dopa
    Michell, A. W.
    Xu, Z.
    Lewis, S. J. G.
    Foltynie, T.
    Williams-Gray, C. H.
    Robbins, T. W.
    Carpenter, R. H. S.
    Barker, R. A.
    EXPERIMENTAL BRAIN RESEARCH, 2006, 174 (01) : 7 - 18
  • [27] Improvement of dyskinesias with l-dopa infusion in advanced Parkinson's disease
    Timpka, J.
    Fox, T.
    Fox, K.
    Honig, H.
    Odin, P.
    Martinez-Martin, P.
    Antonini, A.
    Chaudhuri, K. Ray
    ACTA NEUROLOGICA SCANDINAVICA, 2016, 133 (06): : 451 - 458
  • [28] Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease
    Moser, A
    Siebecker, F
    Vieregge, P
    Jaskowski, P
    Kompf, D
    JOURNAL OF NEURAL TRANSMISSION, 1996, 103 (04) : 421 - 432
  • [29] Effects of subthalamic nucleus stimulation and L-dopa in trunk kinematics of patients with Parkinson's disease
    Ferrarin, M
    Rizzone, M
    Lopiano, L
    Recalcati, M
    Pedotti, A
    GAIT & POSTURE, 2004, 19 (02) : 164 - 171
  • [30] Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration
    Lamberti, P
    Zoccolella, S
    Armenise, E
    Lamberti, SV
    Fraddosio, A
    de Mari, M
    IIiceto, G
    Livrea, P
    EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 (05) : 365 - 368
12345